ArticleBMC cancer2025
VEGFA (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) genotypes in patients with laryngeal squamous cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaryngeal squamous cell carcinoma (LSCC) is a common and aggressive head and neck malignancy with poor prognosis due to late diagnosis and limited biomarkers. Angiogenesis, driven by vascular endothelial growth factor A (VEGFA), plays a key role in tumor growth and metastasis. Single nucleotide variants (SNVs) in the VEGFA gene have been linked to various cancers, but their role in LSCC remains unclear.
methodsIn this study, we investigated the association between VEGFA (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) SNV and LSCC susceptibility in a large cohort of 297 LSCC patients and 390 age- and sex-matched control subjects. The DNA samples were obtained from peripheral blood leukocytes, which were purified using the DNA salting-out technique. Real-time polymerase chain reaction assessed SNVs. The data obtained were processed using the IBM SPSS Statistics 29.0 software. Using a detailed subgroup analysis based on tumor stage, size, metastasis, and differentiation grade, we assessed the potential links between VEGFA (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) variants and LSCC development.
resultsContrary to previous studies suggesting significant associations between VEGFA genetic variances with other squamous head and neck cell cancers, our study found no statistically significant differences in the distribution of these SNVs between LSCC patients and controls. Our findings suggest that VEGFA SNV may not be a key factor in LSCC susceptibility. However, the complexity of LSCC's genetic underpinnings warrants further investigation with larger cohorts and additional genetic markers.
conclusionsOur results contribute to the ongoing debate on the role of angiogenesis in LSCC and provide insights into the challenges of identifying reliable biomarkers for this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.